Marksans Pharma Limited has informed the Exchange regarding a press release dated May 28, 2024, titled "Marksans Pharma Limited s wholly owned subsidiary Relonchem Limited, receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution".